- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.09. | Vertex's midstage data amplify kidney disease market opportunity | ||
| 22.09. | Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets | ||
| 22.09. | Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint | ||
| 22.09. | Roche's GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes | ||
| 22.09. | Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO | ||
| 21.09. | China targets 25% share of global first-in-class drugs in new 5-year plan | ||
| 21.09. | Analysts 'extremely bullish' as Telix beams into Novartis' territory with $1.6B ITM acquisition | ||
| 21.09. | Retension Pharma and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede | ||
| 21.09. | Cue chalks up phase 2 hives win for Xolair challenger | ||
| 18.09. | Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope | ||
| 18.09. | Inside the growing world of biopharma prediction markets | ||
| 18.09. | Xenon Pharmaceuticals pauses phase 3 depression trials after psychosis events | ||
| 18.09. | BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data | ||
| 18.09. | Inflammation biotech Electra Therapeutics charges up with $350M from upsized IPO | ||
| 17.09. | Goa Therapeutics launches with 'immeasurably huge' vision of creating Narcan for alcohol | ||
| 17.09. | After one failed acquisition attempt, Lisata finds lifeline in Marea merger | ||
| 17.09. | North Immunology goes public via reverse merger as eczema drug heads toward clinic | ||
| 17.09. | Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive | ||
| 17.09. | SK pens $315M pact with fellow South Korean company for Parkinson's prospect | ||
| 17.09. | Longeveron's phase 2b stem cell flop spurs cost cutting, exploration of 'all options' | ||
| 16.09. | Novartis ends ALS program after phase 2 flop, adding to R&D woes | ||
| 16.09. | Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier | ||
| 15.09. | FDA launches pilot program to speed up sluggish phase 1 trials | ||
| 15.09. | Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope | ||
| 15.09. | Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.